Alnylam Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

• Alnylam Pharmaceuticals Inc ALNY.OQ reported a quarterly adjusted loss of 44 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -52 cents. The mean expectation of twenty six analysts for the quarter was for a loss of $1.03 per share. Wall Street expected results to range from $-1.85 to -11 cents per share.

• Revenue rose 20.2% to $594.19 million from a year ago; analysts expected $585.82 million.

• Alnylam Pharmaceuticals Inc's reported EPS for the quarter was a loss of 44 cents​.

• The company reported a quarterly loss of $57.48 million.

• Alnylam Pharmaceuticals Inc shares had fallen by 2.5% this quarter and gained 11.9% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 31.7% in the last three months.​

• In the last 30 days, three analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 25 "strong buy" or "buy," 7 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for Alnylam Pharmaceuticals Inc is $324.00

This summary was machine generated from LSEG data May 1 at 01:32 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)